Camber is DSCSA Ready
Camber is fully prepared to meet the new Drug Supply Chain Security Act (DSCSA) requirements, ensuring enhanced traceability, verification, and safety across the pharmaceutical supply chain.
Learn more about how Camber prepared for DSCSA here
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection